The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.
Patricia Ho,Johannes C Melms,Meri Rogava,Chris J Frangieh,Joanna Poźniak,Shivem B Shah,Zachary Walsh,Oleksandr Kyrysyuk,Amit Dipak Amin,Lindsay Caprio,Benjamin T Fullerton,Rajesh Kumar Soni,Casey R Ager,Jana Biermann,Yiping Wang,Mohsen Khosravi-Maharlooei,Giorgia Zanetti,Michael Mu,Hijab Fatima,Emily K Moore,Neil Vasan,Samuel F Bakhoum,Steven L Reiner,Chantale Bernatchez,Megan Sykes,Emily M Mace,Kai W Wucherpfennig,Dirk Schadendorf,Oliver Bechter,Parin Shah,Gary K Schwartz,Jean-Christophe Marine,Benjamin Izar
DOI: https://doi.org/10.1016/j.ccell.2023.05.014
IF: 50.3
2023-01-01
Cancer Cell
Abstract:The cell-autonomous balance of immune-inhibitory and -stimulatory signals is a critical process in cancer immune evasion. Using patient-derived co-cultures, humanized mouse models, and single-cell RNA-sequencing of patient melanomas biopsied before and on immune checkpoint blockade, we find that intact cancer cell-intrinsic expression of CD58 and ligation to CD2 is required for anti-tumor immunity and is predictive of treatment response. Defects in this axis promote immune evasion through diminished T cell activation, impaired intratumoral T cell infiltration and proliferation, and concurrently increased PD-L1 protein stabilization. Through CRISPR-Cas9 and proteomics screens, we identify and validate CMTM6 as critical for CD58 stability and upregulation of PD-L1 upon CD58 loss. Competition between CD58 and PD-L1 for CMTM6 binding determines their rate of endosomal recycling over lysosomal degradation. Overall, we describe an underappreciated yet critical axis of cancer immunity and provide a molecular basis for how cancer cells balance immune inhibitory and stimulatory cues.